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1. Introduction 
Impaired sociability is a domain of psychopathology that contributes significantly to the 
functional disability and poor quality of life of persons with Autism Spectrum Disorders 
(ASDs) (Brodkin, 2007; Crawley, 2004, 2007; Deutsch et al., 2011). Although cognitive 
functioning may influence the expression of impaired sociability, the relationship between 
cognitive deficits and impaired sociability is not a linear one; thus, for example, persons 
with ASDs whose IQs are in the near-normal to above normal range may manifest profound 
deficits of sociability that are similar to those shown by persons with ASDs and intellectual 
disability (Noterdaeme et al., 2010). Currently, there are no approved medications whose 
primary target is the domain of impaired sociability. 
The N-methyl-D-aspartic acid (NMDA) receptor is an example of a glutamate-gated ion 
channel that is comprised of four (or possibly five) constituent polypeptide subunits; it is 
located both pre- and postsynaptically (Millian, 2005). Each constituent polypeptide is an 
integral membrane protein that has external, transmembranous and internal domains. The 
constituent polypeptides align themselves within the lipid bilayer of the membrane to create 
a potential channel, whose opening depends on the membrane potential and the binding of 
L-glutamate and glycine. The duration and frequency of channel opening, which results in 
calcium ion conductance and membrane depolarization, are highly regulated. The 
properties of this ligand-gated ion channel receptor are influenced genetically by the 
combinatorial diversity of the constituent polypeptide subunits (i.e., expression and 
membrane insertion of specific subunits and their splice variants can affect channel 
properties); allosteric modulatory ligands (e.g., neurosteroids) (Deutsch et al., 1992); the 
extent to which the receptor is glycosylated and nitrosylated; and the extent to which the 
internal domain of receptor polypeptide subunits are phosphorylated (Marino & Conn, 
2002). The phosphorylation state of the internal domain is influenced by cross-talk between 
specific signaling pathways and the NMDA receptor; for example, stimulation of 
metabotropic glutamate receptors co-localized with NMDA receptors on the cell surface can 
influence the extent of phosphorylation (Conn et al., 2009a; Marino & Conn, 2002). When the 
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membrane is at its resting potential, a hydrated magnesium ion occupies a binding site 
within the hydrophobic channel domain of the NMDA receptor; this magnesium ion 
blockade is removed as the receptor depolarizes, which may occur as a result of stimulating 
non-NMDA excitatory glutamate-gated ion channel receptors co-localized with NMDA 
receptors on the membrane surface (Chen et al., 1992). Once the magnesium ion blockade is 
removed with “depolarization” of the membrane, L-glutamate and glycine interact 
allosterically with each other to increase the likelihood that the channel will assume an open 
configuration that permits calcium ion conductance (Marino & Conn, 2002). Presynaptically, 
the opening of the NMDA receptor may be involved in calcium ion-dependent release of 
transmitters; channel opening results in the transient increase of the intraneuronal calcium 
ion concentration (Marino & Conn, 2002). Postsynaptically, NMDA receptors located on the 
surface of GABAergic inhibitory neurons contribute to regulation of the inhibitory tone of 
the brain (Benes, 2010). Functionally, because L-glutamate is one of the most abundant 
neurotransmitters in the brain, NMDA receptors are involved in many neural circuits; for 
example, NMDA receptors are necessary for the induction of long-term potentiation in the 
hippocampus and have a major role in spatial memory performance referable to the 
hippocampus, among many other functions (Benes, 2010).  
Targeted mutations in mice that affect expression of the NR1 subunit of the NMDA receptor 
and its affinity for glycine, the obligatory co-agonist that binds to the NR1 subunit and 
contributes to regulation of channel opening, have been created (Halene et al., 2009; Labrie 
et al., 2008). Interestingly, in a standard sociability paradigm, these genetically-engineered 
mice with diminished expression of the NR1 subunit or five-fold diminished affinity of the 
NR1 subunit for glycine show deficits in sociability ((Halene et al., 2009; Labrie et al., 2008). 
Thus, altered NMDA receptor-mediated neurotransmission in mice is associated with 
impaired sociability (e.g., these mutant mice make fewer social approaches and spend less 
time in the vicinity of an enclosed or freely-moving socially-salient stimulus mouse).  
The genetically inbred Balb/c mouse strain displays behavioral hypersensitivity to MK-801 
(dizocilpine), a noncompetitive NMDA receptor antagonist (Billingslea et al., 2003; Burket et 
al., 2010a; Deutsch et al., 1997, 1998). Thus, MK-801 is more potent at antagonizing 
electrically-precipitated seizures in Balb/c mice than a variety of other genetically-inbred 
and outbred mouse strains (Billingslea et al., 2003; Deutsch et al., 1998). Additionally, Balb/c 
mice are more sensitive than other reference mouse strains to the elicitation of irregular 
episodes of intense jumping behavior, which has been referred to as “popping” (Billingslea 
et al., 2003; Deutsch et al., 1997). Further, relative to the outbred Swiss-Webster mouse 
strain, Balb/c mice engaged in more intense MK-801-elicited circling behavior (Burket et al., 
2010a). The heightened behavioral sensitivity of the Balb/c mouse to MK-801 does not 
appear to be due to a “defect” in the receptor itself because a Western Blotting experiment 
revealed no differences in the immunoreactive content of six of the eight identified splice 
variant isoforms of the NR1 subunit, and NR2A and NR2B subunits in the hippocampus 
and cerebral cortex of Balb/c and NIH Swiss mice (Perera et al., 2008). Thus, the altered 
endogenous tone of NMDA receptor-mediated neurotransmission in the Balb/c mouse 
strain may be due to factors “upstream” or “downstream” of the receptor itself. In any 
event, the Balb/c mouse strain, like the targeted genetic mutant mouse strains described 
above, shows quantitative deficits of sociability in a standard mouse paradigm (Burket et al, 
2010b; Brodkin, 2007; Moy et al., 2007; Sankoorikal et al., 2006). These deficits of sociability 
are observable when Balb/c mice are in the presence of a salient social stimulus mouse that 
is either enclosed or allowed to interact freely with a Balb/c mouse (Burket et al., 2010b; 
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Deutsch et al., 2011; Jacome et al., 2011a,b, in press). Specifically, Balb/c mice make fewer 
discrete episodes of social approach and spend less time exploring (sniffing) and in the 
vicinity of an enclosed and freely-moving social stimulus mouse (Jacome et al., 2011; 
Brodkin, 2007). Quite remarkably, D-cycloserine, a partial glycine agonist for the obligatory 
co-agonist binding site, and D-serine, a full agonist for this site that may also be the 
endogenous ligand, were able to attenuate the severity of the Balb/c mouse’s deficits of 
sociability (Deutsch et al., 2011; Jacome et al., 2011a,b). These effects of NMDA receptor 
agonist interventions may be due to direct effects on the sociability deficit itself, as opposed 
to nonspecific effects resulting from increased locomotor activity in general. These 
preclinical results are also consistent with a pilot clinical trial of D-cycloserine 
administration to 10 children with ASDs; in this pilot investigation, D-cycloserine improved 
scores on the social withdrawal subscale of the Aberrant Behavior Checklist (Posey et al., 
2004). Importantly, persons with ASDs may have deficient central inhibitory tone, consistent 
with the high prevalence of co-morbid seizures, which would benefit from an NMDA 
receptor agonist intervention. 
In summary, the Balb/c mouse has emerged as a genetic mouse model of impaired 
sociability that is useful for screening targeted NMDA receptor agonist interventions, which 
may be candidates for development as medications to treat impaired sociability, a 
“neglected” domain of psychopathology in persons with ASDs. The topic areas introduced 
in this overview will be considered below in greater detail.  
2. Impaired glutamatergic transmission may be a shared pathophysiological 
mechanism among persons with diverse etiologies of their autism spectrum 
disorders  
Autism Spectrum Disorders (ASDs) are a heterogeneous group of disorders with respect to 
their clinical presentations that are highly heritable, as shown in family and twin studies 
(Toro et al., 2010); however, with the exception of ASDs occurring in the context of genetic 
disorders due to the effects of a single gene (e.g., tuberous sclerosis), the nature of what is 
inherited and the mode of genetic transmission are usually not known for most patients 
(Toro et al., 2010). Moreover, even in cases where ASDs are due to the effects of a single 
major mutant gene, the steps via which a single mutant gene leads to an autism syndrome 
are also unclear. In spite of the variability of their clinical presentations, persons with the 
diagnosis of an ASD manifest symptoms in three operationally-defined domains of 
psychopathology: “qualitative impairment in social interaction;” “qualitative impairment in 
communication;” and “restricted repetitive and stereotyped patterns of behavior (American 
Psychiatric Association 2000).” Persons with Asperger’s Disorder, however, may have little 
or no clinically significant delays in language and cognitive development. Recent genetic 
investigations suggest that persons with ASDs may have “hotspots” along the genome 
where microdeletions or duplications of DNA, referred to as Copy Number Variations or 
CNVs, are more likely to occur (Bremer et al., 2011). CNVs can lead to problems related to 
“gene dosing effects (i.e., either absent or too much expression of genes that contribute to 
emergence of ASDs)” or, alternatively, can affect the coiling and higher-order structure of 
double-stranded DNA, which, in turn, affects transcription (Toro et al., 2010). Another 
possibility is that a microdeletion can lead to unmasking and unopposed expression of a 
“recessive” mutant gene product, whose homozygous expression may be ordinarily lethal in 
utero. Additionally, since the etiologies of ASDs vary but persons with ASDs share 
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symptoms in the three discrete domains of autism psychopathology, there is interest in 
identifying discrete neural circuits that may serve as the substrate for impaired social-
emotional cognition and other domains of psychopathology in ASDs, irrespective of 
etiology, and exploring the efficiency of synaptic transmission between nodes within these 
neural circuits in affected persons. Thus, imaging studies, such as functional MRI, examine 
activation of specific nodes, such as amygdala, fusiform gyrus, anterior cingulate cortex, 
among other brain areas, while subjects with ASDs view projected images of the human face 
displaying various facial expressions or “affects,” such as fear, anger, disdain or happiness 
(Kleinhans et al., 2011; Ashwin et al., 2007). Moreover, disturbances within circuits may be 
responsible for the abnormal facial scanning strategies persons with ASDs employ (e.g., 
spending less time gazing at the eyes relative to typically developing normal subjects). 
Because pathophysiological abnormalities may represent a common final pathway that 
many persons with ASDs share in-common, irrespective of etiology, it may be possible to 
design medication strategies that target inefficient or aberrant synaptic transmission along 
neural circuits (e.g., the neural circuit necessary for normal social-emotional cognition) that 
would be beneficial for an etiologically diverse group of persons with ASDs (Table 1). 
 
Influence Glutamate Signal Transduction by the NMDA Receptor Itself
 Glutamate Reuptake Inhibitors
 Glycine Reuptake Inhibitors (e.g., sarcosine and sarcosine analogues and derivatives) 
 Glycine Agonists (e.g., D-cycloserine, D-serine)
 Allosteric Modulators of the NMDA Receptor (e.g., neurosteroids, polyamines)  
 Positive Allosteric Modulators of Group I Metabotropic Glutamate Receptors 
 Inhibitors of “Regulator of G Protein Signaling (RGS) Proteins”
  
Influence Downstream of “Defective” NMDA Receptor Signal Transduction Targeting 
GABA Inhibitory Neurons Themselves or Their Downstream Projections and 
Consequences 
 ǂ7 Nicotinic Acetylcholine Receptor Agonist Interventions
 Positive Allosteric Modulators (e.g., galantamine)
 Selective Agonists (e.g., choline, anabaseine derivatives)
 CB1-Cannabinoid Receptor Antagonists 
 Epigenetic Interventions
 Histone Deacetylase Inhibitor
 DNA Methyltransferase 1 Inhibitor
 GABAA Receptor Agonist Interventions
 Selective Benzodiazepine Agonist Interventions 
 Neurosteroids
 
Selective AMPA and Kainate Receptor (i.e., non-NMDA Excitatory Receptor) 
Antagonists  
Table 1. Potential Pharmacological Strategies to Manipulate Endogenous Tone of NMDA 
Receptor-Mediated Neurotransmission 
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Conceivably, impairments of sociability manifested by persons with ASDs reflect disturbances 
within the social-emotional neural circuit (Benes, 2010). Given the quantitative importance of 
glutamatergic transmission in the brain and recent data suggesting that diminished or 
defective expression of the N-methyl-D-aspartic acid (NMDA) subtype of ionotropic 
glutamate receptor is causally-related to deficits of sociability in transgenic mouse strains, the 
NMDA receptor has emerged as a medication target to improve sociability in persons with 
ASDs (Halene et al., 2009; Duncan et al., 2004). More specifically, NMDA receptors are 
involved in regulating presynaptic release of a variety of neurotransmitters, including 
glutamate itself, and their postsynaptic location on the surface of GABA inhibitory neurons 
plays a very important role in regulating central inhibitory tone and critical oscillatory 
rhythms in brain (see below) (Benes, 2010, Deutsch et al., 2010). GABA inhibitory neurons 
project to assemblies of pyramidal neurons and it is the oscillatory firing of these latter 
assemblies of neurons that underlie key rhythms in the brain; the power spectra of gamma 
oscillations are associated with working memory (Benes, 2010; Deutsch et al., 2010). 
Importantly, pyramidal outflow neurons utilize glutamate as their neurotransmitter. 
3. NMDA receptor – Structure and function 
The NMDA receptor is a highly-regulated ligand-gated ion channel that also has features 
of voltage-gating; although it is a ligand-gated ion channel receptor, it does not enjoy the 
close homology and genetic-relatedness that nicotinic acetylcholine and GABAA 
receptors share with each other. However, like other ligand-gated ion channel receptors, 
the NMDA receptor is an oligomeric protein constructed from four constituent 
polypeptide subunits, each of which shares a common motif; nicotinic and GABAA 
receptors have five subunits (Millan, 2005). The receptor polypeptide subunits are 
themselves integral membrane proteins that have an N-terminal extracellular domain, 
four hydrophobic transmembranous domains (in fact, the third hydrophobic loop does 
not span the entire width of the lipid bilayer), and an intracytoplasmic loop that has 
consensus sequences of amino acids that serve as substrates for phosphorylation by 
specific kinases (Conn et al., 2009a; Marino & Conn, 2002). Phosphorylation of the 
intracytoplasmic loop influences the gating and channel properties of the ionophore and 
often occurs as a result of “cross-talk” with G-protein coupled-receptors (GPCR) located 
next to or near the NMDA receptor on the surface of the neuron (Conn et al., 2009a; 
Gregory et al., 2011). The constituent polypeptide subunits align themselves in such a 
manner that they form a potential pore or channel in the membrane, whose opening is 
dependent on the binding of glutamate and its obligatory glycine co-agonist. The 
filtering properties of the channel are such that calcium ions can flux through the open 
channel along their electrochemical gradient. At the ordinary resting membrane 
potential, a hydrated magnesium ion is bound within the channel; in order for the 
channel to become functional, this magnesium ion blockade must be relieved, which 
occurs as the membrane begins to depolarize. Thus, functional conductance through the 
NMDA receptor is dependent on membrane depolarization, which may occur through 
the actions of glutamate stimulating AMPA receptors, another excitatory glutamate-
gated ion channel receptor that may reside in the vicinity of NMDA receptors. The 
functional properties of NMDA receptors themselves are influenced by the unique 
combinations of NR1 splice variant isoforms with NR2A and NR2B receptor subunits 
(Kew & Kemp, 2005). Functional receptors are dependent on inclusion of the NR1 
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subunit or one of its eight common splice variants; the usual combinations comprising 
functional NMDA receptors involve two obligatory NR1 and either two NR2A or two 
NR2B subunits (Kew & Kemp, 2005). Functional NMDA receptors may have two glycine 
binding sites, whose construction depends on the extracellular domains of NR1 subunits, 
and two glutamate binding sites (Kew & Kemp, 2005; Millan, 2005). Also, as noted above, 
the extent to which the intracytoplasmic domain is phosphorylated, and the local pH and 
oxidation potential surrounding the receptor influence the receptor’s channel properties 
(i.e., the likelihood the channel will open and frequency of channel openings in response 
to the binding of glutamate and its obligatory glycine co-agonist to specific sites in the 
extracellular domain of the NMDA receptor)(Millan, 2005; Stephenson, 2006). The 
likelihood that glutamate and glycine will be effective in promoting channel opening is 
also influenced by levels of neurally-active steroids, which act as allosteric modulators 
(Deutsch et al., 1992). Neurally-active steroids are derived from peripheral steroid 
hormones and also are synthesized in situ in the brain by glial cells; the highly-regulated 
translocation of cholesterol across the mitochondrion is the first step in neurosteroid 
biosynthesis in the brain. Clearly, glutamate-gated calcium ion flux across the NMDA 
receptor-associated ionophore is a highly regulated process, subject to genetic influences 
(i.e., combinatorial diversity or the unique combination of receptor polypeptide subunits 
and their splice variants that comprise the receptor and influence its channel properties); 
post-translational modifications (e.g., the extent to which the receptor is phosphorylated 
and nitrosylated); and circulating levels of endogenous allosteric modulators (e.g., 
neurosteroids and polyamines, such as spermidine) (Conn et al., 2009a; Deutsch et al., 
1992; Kew & Kemp, 2005, Millan, 2005; Stephenson, 2006).  
NMDA receptors have both pre- and postsynaptic localizations on neurons. Presynaptically, 
NMDA receptors may participate in neurotransmitter release, a process dependent on 
calcium ions, whereas postsynaptically, their location on GABAergic neurons may 
contribute to the regulation of inhibitory tone and normal oscillatory activity in brain 
(Deutsch et al., 2010). Interestingly, seizures occur commonly in persons with autism 
spectrum disorders, consistent with diminished central inhibitory tone; also, the normal 
gamma oscillatory rhythm and power spectra of gamma oscillations, an important 
oscillatory rhythm associated with working memory and higher executive functions, are 
dependent on functional GABAergic projections to assemblies of pyramidal cell output 
neurons (Deutsch et al., 2010). Thus, the integrity of circuits necessary for normal cognition 
and social behavior, whose nodes include cerebral cortex, anterior cingulate gyrus, 
hippocampus, and amygdala, among other discrete anatomic brain regions, contain NMDA 
receptors (Benes, 2010). An emerging body of preclinical and clinical data suggests that 
NMDA receptor hypofunction at the level of the receptor itself or due to abnormalities 
upstream or downstream of the receptor contributes to both cognitive problems and 
impaired sociability (Darrah et al., 2008; Deutsch et al., 2011; Halene et al., 2009; Jacome et 
al., 2011b; Labrie et al., 2008).  
The ability of glycine to make glutamate a more efficient neurotransmitter and, thereby, 
increase the likelihood the channel will transiently assume an open configuration and 
allow calcium ions to flux freely has aroused interest in the strychnine-insensitive 
obligatory glycine co-agonist binding site on the NMDA receptor as a target for 
medication development to address presumptive NMDA receptor hypofunction. The 
strychnine-insensitive glycine binding site on the NMDA receptor is also referred to as the 
glycineB site (Millan, 2005). Interestingly, D-serine may be the naturally-occurring and 
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preferred ligand for the glycine binding site on the NMDA receptor; a racemase exists that 
converts the more commonly-occurring L-form of serine, which is incorporated into 
protein and extensively involved in intermediary metabolism, to the D-form, which may 
have a unique localization and function within brain (Jacome et al., 2011b; Long et al., 
2006). Exogenously-administered D-serine and other directly acting full agonists may 
serve as “proofs of concept” to implicate NMDA receptor hypofunction in some aspects of 
the pathophysiology of autism spectrum disorders, especially in animal models studying 
the effects of their single dose administration on outcome measures related to sociability 
and cognition (Jacome et al., 2011b). However, directly-acting full glycineB agonists may 
have limitations with respect to their development as medication interventions, which 
would have to be administered chronically in disorders such as autism spectrum 
disorders, because of concerns about “agonist-induced” receptor desensitization and 
excitotoxicity (Jacome et al., 2011b). Thus, in terms of viable medication strategies, there is 
interest in partial glycine agonists (e.g., D-cycloserine), and influencing NMDA receptor 
channel properties indirectly through “cross-talk” with other receptors (e.g., strategies 
exploring administration of positive allosteric modulators [PAMs] of type 1 metabotropic 
glutamate receptors [mGluRs]). Specifically, our laboratory is interested in exploring the 
effect of PAMs of mGluR5 on the impaired sociability of Balb/c mice, a genetic mouse 
model of autism spectrum disorders, because mGluR5 stimulation leads to 
phosphorylation of a specific serine residue within the intracytoplasmic domain of the 
NR1 subunit (Takagi et al., 2010). In general, as members of class “C” G-protein coupled-
receptors, mGluR5 receptors are constitutive dimers that are located postsynaptically in 
close functional proximity to NMDA receptors. They have a large extracellular ‘venus 
flytrap domain (VFD)’ that is the L-glutamate agonist recognition site; binding of  
L-glutamate leads to the propagation of a conformational change via ‘cysteine-rich 
domains (CRD),’ resulting in activation of phospholipase Cǃ through its coupling to 
ligand-binding by a Gq, a specific GTP binding protein (Niswender & Conn, 2010). A 
downstream consequence of phospholipase activation includes increased phosphorylation 
of the NMDA receptor. There are many functional consequences of increasing the 
phosphorylation status of NMDA receptors, several of which may be relevant to domains 
of psychopathology present in ASDs. For example, MK-801 can disrupt cognitive 
flexibility or set-shifting ability; the severity of this disruption can be attenuated by a 
positive allosteric modulator of mGluR5 receptors (Darrah et al., 2008). Presumably, this 
positive therapeutic effect reflects the increased phosphorylation state of NMDA 
receptors. As will be discussed, functional NMDA receptors and “normal” tone of 
endogenous NMDA receptor-mediated neurotransmission are necessary for “normal” 
sociability in mice. 
4. NMDA receptor and genetic mouse models of autism spectrum disorders 
The NMDA receptor has emerged as a promising target for medication strategies 
designed to improve sociability (and cognition) in studies involving both genetically-
engineered and inbred mouse strains, and other rodent species (Blundell et al., 2010; 
Deutsch et al, 2011; Darrah et al., 2008; Halene et al., 2009; Jacome et al., 2011b; Labrie et 
al., 2008). Importantly, the NMDA receptor is known to be involved in important aspects 
of electrophysiology relevant to cognition (e.g., induction of long-term potentiation in the 
hippocampus) and memory performance (e.g., hippocampally-dependent spatial 
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memory). These findings were complemented with relatively recent investigations 
showing transgenic mice with diminished expression of the NR1 subunit of the NMDA 
receptor (~5 to 10% of normal levels of expression) or five-fold diminished affinity of the 
receptor for glycine as a result of targeted mutagenesis of the glycine binding domain on 
the NR1 subunit have quantitative deficits of sociability in a standard paradigm (Halene 
et al., 2009; Labrie et al., 2008). Perhaps, of even greater significance, a targeted NMDA 
receptor agonist intervention (i.e., D-cycloserine) attenuated measurable deficits of 
sociability in “genetically-normal” resident and intruder mice in a standardized social 
interaction paradigm (McAllister, 1994). Thus, even in the absence of a genetic lesion 
affecting the NMDA receptor itself, this receptor could serve as a target to improve 
sociability and cognition. Additionally, encouraging data are emerging from studies with 
genetic mouse models of autism spectrum disorders, which are neurodevelopmental 
disorders, that pharmacotherapeutic interventions can improve quantitative deficits of 
sociability in young adult mice (Deutsch et al., 2011; Jacome et al., 2011a,b; Sankoorikal et 
al., 2006). Thus, there is reason for optimism with respect to potential for effectiveness of 
newly-developed medications identified in standard sociability paradigms using 
transgenic and inbred mouse strains as subjects; unfortunately, autism spectrum disorders 
are not often recognized in preschool-age children and, as a result, treatment is often 
delayed, which is why the positive data with young adult mice are so encouraging. 
5. Sociability paradigm 
Our laboratory has adopted a recently established mouse behavioral procedure for the 
quantitative assessment of sociability (Brodkin, 2007; Burket et al., 2010b; Crawley, 2004, 
2007; Deutsch et al., 2011; Jacome et al., 2011b; Moy et al., 2007; Sankoorikal et al., 2006; 
Silverman et al., 2010). Briefly, in the first session, a test mouse is placed in the middle 
compartment and allowed to acclimate to the sociability apparatus for 5 minutes. In the 
second 5-minute session, a stimulus mouse is enclosed in an inverted wire cup in the side 
designated as the social compartment, and an empty inverted wire cup is placed in the side 
designated as the nonsocial compartment. The side designated for the location of the 
enclosed stimulus mouse is randomly assigned in a counterbalanced fashion throughout the 
experiment. In the third 5-minute session, the stimulus mouse is released from the inverted 
wire cup, and the test and stimulus mice are allowed to interact freely with each other 
(Figure 1). All sessions are conducted in dim lighting and videotaped for future viewing and 
data collection. 
The amount of time a test mouse spends in the social and nonsocial compartments and 
exploring (sniffing) the inverted wire cups is measured in session II. Locomotor activity is 
measured in all three sessions and is defined as the number of transitions (i.e., number of 
times all four extremities cross each compartment) the test mouse makes across all three 
compartments in each 5-min session. Other behavioral measures of the test mouse include 
additional measures of sociability (i.e., social approach, social avoidance, social pursuit, 
mounting and anogenital sniffing) and stereotypic behaviors (i.e., rearing, grooming and 
wall climbing), which are obtained during the 5-minute session of free interaction 
between test and stimulus mice (Table 2). Importantly, our laboratory showed that these 
behavioral measures can be reliably rated by independent observers (Jacome et al., in 
press).  
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Fig. 1. Sociability paradigm 
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Measures of Sociability 
Social approach 
A social behavior of test and stimulus mice defined as a discrete 
episode of their initiation of sniffing within a two-cm vicinity of each 
other. 
Social 
avoidance 
A nonsocial response of the test mouse defined as a discrete episode of 
freezing, withdrawing, or turning its head away while within a two-cm 
vicinity of the socially-salient stimulus mouse. 
Social Pursuit 
A measure of the time that the test mouse spends following or chasing 
the socially-salient stimulus mouse from initiation of the encounter 
until both mice separate by a distance of at least two cm. 
Anogenital 
sniffing 
A social behavior displayed by the test mouse defined as a discrete 
episode of sniffing the anogenital area of the stimulus mouse within a 
two-cm vicinity. 
Mounting 
A social behavior displayed by the test mouse defined as a discrete 
episode of placing the front paws on the stimulus mouse. 
Measures of Stereotypic Behaviors 
Rearing 
A stereotypic behavior displayed by the test mouse defined as a 
discrete episode of raising forelimbs and standing on hindlimbs. 
Grooming 
A stereotypic behavior displayed by the test mouse defined as a 
discrete episode of licking itself. 
Wall climbing 
A stereotypic behavior displayed by the test mouse defined as a 
discrete episode of raising forelimbs and placing front paws on walls of 
the sociability apparatus.  
Table 2. Measures of Sociability and Stereotypic Behavior 
6. The genetically-inbred balb/c mouse, a mouse strain that is behaviorally-
hypersensitive to mk-801 (dizocilpine), a noncompetitive nmda receptor 
antagonist, shows quantitative deficits of sociability 
Over the past 20 years, our laboratory has been exploring the effects of stress on the 
abilities of flurazepam, a benzodiazepine agonist, and MK-801 (dizocilpine), a 
noncompetitive NMDA receptor antagonist, to antagonize electrically-precipitated tonic 
hindlimb extension in mice (Billingslea et al., 2003; Burket et al., 2009; Deutsch et al., 1990; 
1998). These studies showed that 24 hours after mice are forced to swim for up to 10 
minutes in cold (6°C) water, the abilities of flurazepam and MK-801 to antagonize 
electrically-precipitated seizures are reduced. During the course of these investigations, it 
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was observed that the genetically-inbred Balb/c mouse strain showed increased 
sensitivity to MK-801 administration on several behavioral measures. For example, 
relative to other inbred and outbred strains, the potency of MK-801 to raise the threshold 
voltage for elicitation of tonic hindlimb extension was greater in the Balb/c mouse 
(Billingslea et al., 2003; Deutsch et al., 1998). Similarly, Balb/c mice were more sensitive to 
the ability of MK-801 to elicit irregular episodes of intense jumping behavior, referred to 
as “popping,” and “circling” behavior than other comparator strains (Billingslea et al., 
2003; Burket et al., 2010a; Deutsch et al., 1997). The increased sensitivity to behavioral 
effects of MK-801 suggested to us that there is something “altered” in the endogenous 
tone of NMDA receptor-mediated neurotransmission in the Balb/c strain, relative to the 
other strains that we examined. Surprisingly, when we studied the immunoreactive 
protein content of six of the eight common splice variant isoforms of the NR1 subunit and 
NR2A and NR2B subunits in hippocampi and cerebral cortices from Balb/c and an 
outbred comparator strain, no significant differences were evident (Perera et al., 2008). 
These data suggested to us that the presumed altered endogenous tone of NMDA 
receptor-mediated neurotransmission in the Balb/c mouse was not at the level of the 
NMDA receptor itself (e.g., due to altered expression of the receptor polypeptide 
subunits), but, perhaps, at synapses upstream or downstream of the location of the 
receptor.  
Because of our interest in the Balb/c mouse, we replicated reports that this mouse strain 
showed quantitative deficits of sociability in a standard paradigm (Brodkin, 2007; Moy et al., 
2007; Sankoorikal et al., 2006), and extended these observations to include a detailed study 
of its locomotor activity in the presence of an enclosed salient social stimulus mouse and 
when Balb/c and stimulus mice are allowed to interact freely with each other. These studies 
showed that the locomotor activity of the Balb/c mouse strain is suppressed in the presence 
of a social stimulus mouse, which serves as another quantitative measure of impaired 
sociability (Burket et al., 2010b). The Balb/c mouse makes fewer discrete episodes of social 
approach, displays more social avoidance, and spends less time exploring and in the vicinity 
of both an enclosed and freely-behaving social stimulus mouse, than the outbred Swiss 
Webster comparator strain (Deutsch et al., 2011; Jacome et al., 2011b; submitted manuscript). 
Moreover, the impaired sociability of the Balb/c mouse affects the behavior of the social 
stimulus mouse when they are allowed to freely interact with each other for five minutes 
(Jacome et al., in press); thus, the social stimulus mouse will make significantly more 
discrete episodes of social approach toward the Balb/c test mouse than toward the outbred 
Swiss Webster comparator strain during this period of free interaction. The Balb/c mouse 
also demonstrates less anogenital sniffing and “mounting (i.e., placing forepaws on the 
stimulus mouse)” of the stimulus mouse, compared with the outbred Swiss Webster 
comparator strain. Another interesting behavioral feature of the Balb/c mouse is the 
dissociation between impaired sociability and intensity of spontaneous self-grooming 
behavior and other stereotypic behaviors (Jacome et al., in press). Thus, relative to the 
outbred Swiss Webster comparator strain, the Balb/c mouse spends less time engaged in 
spontaneous self-grooming and other stereotypic behaviors during the five-minute period of 
free interaction between test (i.e., Balb/c or Swiss Webster) and social stimulus (i.e., ICR 
strain) mice. This latter finding was unexpected in view of the fact that stereotypies (e.g., 
hand-flapping) are frequently observed among persons with autism spectrum disorders; 
self-grooming, rearing, and wall-climbing are examples of stereotypic behaviors measured 
in mice.  
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Because the Balb/c mouse is behaviorally-hypersensitive to MK-801, suggesting an altered 
endogenous tone of NMDA receptor-mediated neurotransmission, we wondered if 
pharmacological interventions targeting the NMDA receptor would affect its social behavior 
in a standard paradigm. The initial study examined D-cycloserine (320 mg/kg, 
intraperitoneally), a partial glycine agonist. This study confirmed that 8-week old male 
Balb/c mice made significantly fewer discrete episodes of operationally-defined social 
approach toward a 4-week old male ICR social stimulus mouse when the two were allowed 
to interact freely with each other, compared with the same measure of social approach of 8-
week old male Swiss Webster mice in the same paradigm (Deutsch et al., 2011). Remarkably, 
however, the number of discrete episodes of social approach toward the social stimulus 
mouse made by Balb/c mice treated with D-cycloserine (320 mg/kg, intraperitoneally) did 
not differ from the vehicle-treated Swiss Webster mice. Moreover, the locomotor activity of 
D-cycloserine-treated Balb/c mice in the presence of both an enclosed and freely-behaving 
social stimulus mouse did not differ from the locomotor activity of vehicle-treated Swiss 
Webster mice under the same conditions. Thus, D-cycloserine attenuated the severity of 
several quantitative measures of the Balb/c mouse’s deficit of sociability, restoring these 
measures to levels observed in vehicle-treated Swiss Webster mice, the outbred comparator 
strain (Deutsch et al., 2011). In further studies with D-cycloserine designed to explore 
possible mechanisms of its effect(s) and an explanation for the Balb/c mouse’s deficit of 
sociability, we showed that Balb/c mice did not differ from Swiss Webster mice in terms of 
time spent exploring an inanimate object, whereas, as expected, Balb/c mice spent 
significantly less time exploring an enclosed social stimulus mouse (Jacome et al., 2011a). 
Moreover, the Balb/c mouse’s deficit in time spent in social exploration was not an 
epiphenomenon of a greater basal level of “anxiety” because Balb/c mice did not spend less 
time in the open arms of an elevated plus maze than the Swiss Webster comparator strain. 
Also, D-cycloserine (320 mg/kg, intraperitoneally) significantly increased the number of 
open-arm entries of both strains of mice, suggesting that it causes a general increase in 
exploratory activity that was not strain-specific. However, there was something unique 
about a social stimulus mouse’s ability to suppress the locomotor activity of the Balb/c 
strain and D-cycloserine’s strain-selective ability to increase social exploration in the 
genetically-inbred, sociability-impaired Balb/c strain; there was no similar D-cycloserine-
induced increase of social exploration in the Swiss Webster strain (Jacome et al., 2011a). 
In addition to D-cycloserine, our laboratory showed that D-serine (560 mg/kg, 
intraperitoneally), a full glycine agonist, attenuated the severity of deficits of sociability in 
the Balb/c strain (Jacome et al., 2011b). The ability of D-serine to do this serves as an 
important “proof of concept” that targeted NMDA receptor agonist interventions can 
improve sociability in a genetic mouse model with presumed disturbance of endogenous 
NMDA receptor-mediated neurotransmission. Additionally, D-serine, like D-cycloserine, 
improved sociability in young adult 8-week old mice that serve as a genetic mouse model 
for at least some dimensions of autism spectrum disorders; these data encourage 
development of medication interventions in a neurodevelopmental disorder. Specifically, D-
serine increased the amount of time Balb/c mice spent both in the compartment containing 
the enclosed social stimulus mouse and the amount of time Balb/c mice spent actually 
exploring and sniffing the enclosed social stimulus mouse (Jacome et al., 2011b). 
Importantly, the Swiss Webster comparator strain spent significantly more time in the 
compartment containing the enclosed social stimulus mouse and spent significantly more 
time exploring and sniffing this enclosed mouse even in the vehicle-treated condition. 
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However, as noted earlier, there are serious concerns with the development of a full agonist 
for the treatment of a chronic neuropsychiatric/neurodevelopmental disorder, such as an 
autism spectrum disorder. Specifically, a full agonist may have diminished 
efficacy/effectiveness over time because of agonist-induced desensitization, and a full 
agonist may cause excitotoxicity. Thus, D-cycloserine, a partial glycine agonist, may be 
expected to better retain efficacy/effectiveness upon chronic administration, while not being 
associated with increased risk for excitotoxicity; however, this is an empirical question that 
we will pursue in future studies. 
As discussed, the mGluR5 receptor is functionally coupled to NMDA receptors; mGluR5 is a 
GPCR that is coupled to a Gq protein, whose biochemical effector is phospholipase Cǃ 
(Borowicz et al., 2009; Niswender & Conn, 2010). Importantly, in addition to stimulating 
phosphorylation of a serine residue in the intracytoplasmic domain of the NR1 subunit of 
the NMDA receptor and, thereby, increasing the sensitivity of the NMDA receptor to 
stimulation by glutamate and glycine, mGluR5 receptors also play an important role in 
regulating translation of proteins in the basilar dendrites of pyramidal cell neurons. 
Stimulation of the mGluR5 receptor promotes protein synthesis (Bear et al., 2004; Dölen et 
al., 2010); thus, mGluR5’s promotion of protein synthesis is unopposed in persons with 
Fragile X Syndrome, who are deficient in expression of the ‘fragile X mental retardation 
protein.” A major role of the ‘fragile X mental retardation protein’ is to dampen protein 
synthesis in basilar dendrites through its interaction and interference with the function of 
polyribosomes (Bear et al., 2004; Dölen et al., 2010). Because an unbalanced increase in 
protein synthesis in basilar dendrites is thought to contribute to the pathophysiological 
disturbance of Fragile X Syndrome, which has a high co-morbid prevalence of autism 
spectrum disorders, mGluR5 antagonism is emerging as a promising therapeutic strategy 
for this X-linked disorder.  
The high comorbid prevalence of autism spectrum disorders among persons with Fragile X 
Syndrome and the beneficial effect of mGluR5 antagonism in mouse models of Fragile X 
Syndrome stimulated exploration of mGluR5 antagonism in another genetically-inbred mouse 
model of autism spectrum disorders (Silverman et al., 2010). Specifically, in a recent study, 2-
methyl-6-(phenylethynyl)-pyridine (MPEP), an mGluR5 receptor antagonist that is centrally 
available after peripheral administration, was shown to attenuate the severity of self-grooming 
in BTBR T + tfj (BTBR) mice, an inbred genetic mouse model of autism spectrum disorders; the 
intervention did not affect locomotor activity nor did it have an effect on the impaired 
sociability of this mouse strain (Silverman et al., 2010). Repetitive self-grooming is thought to 
reflect and model the symptom domain of “restricted repetitive and stereotyped patterns of 
behavior,” which is an important dimension of psychopathology in autism spectrum 
disorders. (In fact the text revision of the fourth edition of the American Psychiatric 
Association’s Diagnostic and Statistical Manual requires that definitional criteria for at least 
one item/symptom in this domain must be fulfilled in order to assign a diagnosis of “autistic 
disorder.”) Importantly, the BTBR mouse strain, in contrast to the Balb/c mouse strain, 
showed more intense repetitive self-grooming behavior than the comparator C57BL/6J mouse 
strain used in these studies (Silverman et al., 2010), the latter is a mouse strain characterized as 
displaying “high-sociability.” Because of the interest in MPEP as a pharmacological 
intervention for a significant domain of autism psychopathology (i.e., “restricted repetitive and 
stereotyped patterns of behavior”), our group decided to study the effect of MPEP (30 mg/kg, 
intraperitoneally-administered) on measures of sociability and stereotypies, including 
spontaneous self-grooming behavior, in test mice (i.e., Balb/c or Swiss Webster) while they 
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interacted freely with stimulus mice (i.e., ICR mice); as noted MPEP is a relatively selective, 
potent (IC50 value in the 30 nM range), blood-brain barrier permeable noncompetitive mGluR5 
antagonist (Gasparini et al., 1999). Because the baseline level of stereotypies in the Balb/c 
strain is low, it is hard to detect drug effects on stereotypy outcome measures in this strain. 
However, the findings in the comparator Swiss Webster strain on reduction of stereotypies 
and worsening of some measures of sociability by MPEP underscore the need for caution in 
the development of mGluR5 antagonists as medications for the treatment of ASDs. 
Importantly, MPEP significantly reduced stereotypies in the Swiss Webster comparator strain, 
suggesting that this domain of autism spectrum disorder psychopathology may be uncoupled 
from sociability, reflecting, perhaps, their differences in underlying circuitry. MPEP also had 
socially disruptive effects in both strains (Burket et al., submitted manuscript), as well as some 
positive effects on sociability, thus, while MPEP attenuated stereotypies that appeared 
spontaneously during social interaction in both strains, it also had complex and inconsistent 
effects, including worsening, on sociability. 
Given the role of the NMDA receptor for the display of normal sociability, these data add 
a cautionary note with respect to the pursuit of an mGluR5 antagonist medication strategy 
in autism. As a result of “cross-talk” between mGluR5 and NMDA receptors, stimulation 
of mGluR5 can promote phosphorylation of a serine residue in the intracytoplasmic 
domain of the NR1 subunit, which should result in “activation” of the NMDA receptor 
and its greater sensitivity to channel opening in response to glutamate and glycine (Mario 
& Conn et al., 2002). Moreover, MPEP is believed to exert its mGluR5 inhibitory 
properties by binding or interacting with a site in the seven transmembranous 
hydrophobic domain that is also the site of action of several positive allosteric modulators 
(PAMs) of mGluR5 (Conn et al., 2009b). Given the fact administration of glutamate 
“agonists” lack specificity and bind to a diverse variety of metabotropic and ionotropic 
glutamate receptors, in addition to their potential for excitotoxicity, interest has shifted to 
development of positive and negative allosteric modulators to selectively increase and 
decrease, respectively, signal transduction by metabotropic glutamate receptors (Conn et 
al., 2009a). Unlike the agonist recognition sites themselves that show conservation of their 
electronic architecture for recognition of glutamate and its analogues, allosteric 
modulatory sites show diversity of structure among glutamate receptors, affording 
“selectivity (i.e., only selected metabotropic and ionotropic glutamate receptors will be 
targeted).” Also, allosteric modulators are only effective in the presence of the 
endogenous agonist (Conn et al., 2009a); thus, they will be effective only at the precise 
synapse that glutamate (and glycine) is released, preserving the temporal and spatial 
constraints that are so critical to efficient, as opposed to “leaky,” synaptic transmission. 
We and others are beginning to explore the potential therapeutic role of positive allosteric 
modulators of mGluR5 as a medication strategy to address presumptive NMDA receptor 
hypofunction in autism spectrum disorders.  
7. Future directions and translational applications 
Targeting the NMDA receptor and circuits containing and utilizing the NMDA receptor for 
synaptic transmission remain a promising area of future investigations. Very importantly, 
preclinical studies must also include chronic dosing conditions and the demonstration of 
sustained efficacy. Viable strategies should include manipulations both upstream and 
downstream of the presumed location of NMDA receptors on the surface of GABA 
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inhibitory neurons, especially the “fast-spiking (FS),” parvalbumin-containing GABA 
neurons that regulate assemblies of pyramidal outflow neurons and underlie gamma 
oscillations (Benes et al., 2010). (In addition to NMDA receptors, specific kainate receptors, 
another type of ionotropic glutamate receptor, on the surface of GABA inhibitory 
interneurons [e.g., GluR6-containing kainate receptors] may also contribute to the 
generation and regulation of important oscillatory rhythms in brain.)  
Thus, future studies can explore the acute and chronic consequences of both reducing 
(e.g., stimulating glutamate reuptake with guanosine) and increasing (e.g., via specific 
glutamate reuptake inhibitors) the concentration of glutamate within the synaptic cleft. 
Moreover, in addition to stimulation of the glycineB site with agonists, a strategy that is 
supported by the results of the D-serine and D-cycloserine experiments discussed in this 
review, interference with presynaptic reuptake of glycine via the use of glycine-1 
transporter inhibitors (e.g., sarcosine and its derivatives) is another approach. We have 
reviewed the rationale underlying the use of PAMs of mGluR5 above; this strategy could 
conceivably be expanded or complemented by strategies that inhibit the activities of 
specific “regulators of G protein signaling (e.g., RGS4).” “Regulators of G protein 
signaling” promote the activities of GTPase and, thereby, dampen production of the 
soluble intracellular secondary messengers, whose synthesis is activated by glutamate’s 
stimulation of metabotrobic glutamate receptors. The genetically-inbred, sociability-
impaired Balb/c mouse may also be used to study the effects of neurosteroids on 
sociability; neurosteroids act at the level of cell surface ionotropic receptors (e.g., GABAA 
and NMDA receptors) to influence ion flux and membrane potential in subtle ways. 
Other strategies could include downstream manipulations; for example, if the 
GABAergic neurons containing NMDA receptors on their surface are dysfunctional, 
selective benzodiazepine agonist interventions could be considered (e.g., agonists that 
target GABAA receptors containing ǂ3 or ǂ5 subunits) that would promote GABAergic 
transmission downstream, via bypassing or compensating for the “defective” GABA 
inhibitory neuron. Additionally, if release of GABA is diminished, downstream 
glutamatergic projections could be relieved of critical GABAergic inhibition, which 
might be addressed by selective glutamate receptor antagonists that would block or 
attenuate the consequences of excessive downstream release of glutamate. Clearly, this is 
a highly speculative discussion, but the availability of genetic mouse models of autism 
spectrum disorders in general, and impaired sociability in particular, tested in a standard 
paradigm to assess sociability encourage and make this type of systematic examination 
possible.  
There are provocative data suggesting that D-cycloserine improved social withdrawal in a small 
sample of 10 children with autism (Posey et al., 2004). Clearly, the therapeutic effect of a 
medication in this neurodevelopmental disorder is expected to be small and clinical trials must 
minimize “noise” associated with subject differences that may obscure a positive effect of 
treatment. Nonetheless, a medication that targets domains of sociability and cognition in the 
context of a well-designed interdisciplinary, individualized treatment plan that includes 
components of special education, speech and language therapy, occupational therapy and 
vocational assessment and training may contribute to significantly improved quality of life for 
many persons suffering with autism spectrum disorders. An outline for an integrated 
therapeutic strategy to address the sociability deficit of persons with autism spectrum disorders 
is shown in Table 3; clearly, medications will be only one component, albeit an important one, 
of a comprehensive individualized, interdisciplinary, multimodal treatment plan.  
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The NMDA receptor contributes to regulation of central inhibitory tone by influencing the 
firing of GABA inhibitory neurons. In addition to NMDA receptors, other receptors on the 
surface of the GABA inhibitory neuron may represent promising pharmacotherapeutic 
targets. In particular, the ǂ7 subunit-containing nicotinic acetylcholine receptor (ǂ7 nAChR), 
like the NMDA receptor, is a ligand-gated primarily calcium ion channel receptor on the 
surface of GABA inhibitory neurons that is emerging as a promising target. Recent efficient, 
high-throughput strategies for interrogating the human genome in large populations of 
referred persons with developmental disabilities showed that microdeletions of 15q13.3 (i.e., 
copy number variants), the locus of the ǂ7 nAChR, are associated with presentations of 
ASDs, which lend genetic support for the development of medications that target the 
ǂ7nAChR. Hopefully, medication development strategies that exploit these promising 
genetic leads in appropriate mouse models will lead to improved treatments and outcomes 
for ASDs (Deutsch et al., submitted for publication).  
 
Adjunctive Medication Strategies 
 Targeted NMDA Receptor Agonist Intervention 
  Primary defect in social motivation 
   
 Atypical Antipsychotic Medications 
  Stereotypies, irritability and other behaviors that interfere with 
learning and socialization 
   
 Anxiolytics
  Social anxiety 
   
 Selective Serotonin Reuptake inhibitors 
  Rituals, repetitive behaviors, sadness and depression  
  Social anxiety 
   
Medications are one important component of an individualized, multi-modal, 
interdisciplinary treatment plan that includes, but is not limited to: 
 Special Education 
 Psychosocial Skills Training  
 Operant/Instrumental Learning Interventions 
 Vocational Rehabilitation 
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